Abstract
Penfluridol is a diphenylbutylpiperdine derivative with a half-life of sixty-six (66) hours. The present study was designed to determine its efficacy for the maintenance of schizophrenia. In a 52 week double-blind study, once weekly doses of penfluridol were compared with once daily doses of chlorpromazine in 56 schizophrenic patients receiving maintenance treatment on an outpatient basis. Both drugs were similar in their clinical effectiveness; no major side effects occurred with either drug.
Publication types
-
Clinical Trial
-
Comparative Study
-
Controlled Clinical Trial
MeSH terms
-
Adult
-
Chlorpromazine / adverse effects
-
Chlorpromazine / therapeutic use
-
Clinical Trials as Topic
-
Dose-Response Relationship, Drug
-
Double-Blind Method
-
Drug Evaluation
-
Female
-
Humans
-
Male
-
Penfluridol / adverse effects
-
Penfluridol / therapeutic use*
-
Piperidines / therapeutic use*
-
Psychiatric Status Rating Scales
-
Psychotic Disorders / drug therapy*
-
Schizophrenia / drug therapy*
Substances
-
Piperidines
-
Penfluridol
-
Chlorpromazine